PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
Status:
Completed
Trial end date:
2019-10-28
Target enrollment:
Participant gender:
Summary
This study intends to investigate whether addition of PEG-IFN alfa-2a in HBeAg-negative
chronic hepatitis B patients who are pretreated with nucleos(t)ide analogues enhances the
degree of HBsAg decline.